Posted by Michael Wonder on 03 Aug 2022
MediWound announces US FDA acceptance of biologics license application for NexoBrid for the treatment of severe thermal burns
3 August 2022 - Prescription Drug User Fee Act target date of 1 January 2023.
MediWound today announced that the U.S. FDA has accepted for review its recently re-submitted biologics license application for NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
